Zenas BioPharma (ZBIO) Other Non-Current Assets (2023 - 2026)

Zenas BioPharma's Other Non-Current Assets history runs 4 years deep, the most recent figure standing at $14.5 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 6854.55% year-over-year to $14.5 million in Q1 2026; TTM through Mar 2026 was $14.5 million, a 6854.55% increase from a year earlier, with the FY2025 full-year figure at $13.8 million, up 7.41% from the prior year.
• Other Non-Current Assets advanced to $14.5 million in Q1 2026 per ZBIO's latest filing, from $13.8 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $14.5 million in Q1 2026 and bottomed at $83000.0 in Q3 2025.
• The 4-year median for Other Non-Current Assets is $5.8 million (2023), against an average of $6.6 million.
• Across the five-year window, Other Non-Current Assets retreated 6.74% in 2025 and jumped 6854.55% in 2026, its largest moves.
• Year by year, Other Non-Current Assets stood at $5.8 million in 2023, then soared by 122.11% to $12.9 million in 2024, then gained by 7.41% to $13.8 million in 2025, then increased by 5.26% to $14.5 million in 2026.
• Per Business Quant, the three latest ZBIO Other Non-Current Assets figures stand at $14.5 million (Q1 2026), $13.8 million (Q4 2025), and $83000.0 (Q3 2025).